



- (51) **International Patent Classification:**
G01N 33/50 (2006.01) *G01N 33/74* (2006.01)
- (21) **International Application Number:**
PCT/US2025/013871
- (22) **International Filing Date:**
30 January 2025 (30.01.2025)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/627,359 31 January 2024 (31.01.2024) US
- (71) **Applicant: BLUEROCK THERAPEUTICS LP**
[US/US]; 238 Main Street, 3rd Floor, Cambridge, Massachusetts 02142 (US).
- (72) **Inventors: SRINIVAS, Maya;** c/o BlueRock Therapeutics LP, 238 Main Street, 3rd Floor, Cambridge, Massachusetts 02142 (US). **EBEL, Mark;** c/o BlueRock Therapeutics LP, 238 Main Street, 3rd Floor, Cambridge, Massachusetts 02142 (US). **WILKINSON, Dan;** c/o BlueRock Therapeutics LP, 238 Main Street, 3rd Floor, Cambridge, Massachusetts 02142 (US). **TOMISHIMA, Mark;** c/o BlueRock Therapeutics LP, 238 Main Street, 3rd Floor, Cambridge, Massachusetts 02142 (US). **ADAMS, Nathaniel, Alexander;** c/o BlueRock Therapeutics LP, 238 Main Street, 3rd Floor, Cambridge, Massachusetts 02142 (US).
- (74) **Agent: ABU-SHAAR, Muna et al.;** Biospark Intellectual Property Law, 1 Broadway, 14th Floor, Cambridge, Massachusetts 02142 (US).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) **Title:** IGFBP2 IN CELL CULTURE




FIG. 1

(57) **Abstract:** The present disclosure relates to methods for measuring IGFBP2 concentrations in cell cultures and applications thereof, e.g., for estimating the numbers of cells in culture, assessing the health of cells in culture, normalizing data from different experiments, and evaluating production of secreted molecules.

[Continued on next page]

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*